{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-23-000076","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2023-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.404599+00:00","generated_at":"2026-06-14T01:01:36.862269+00:00","sec_items":["1.01","2.03","5.07","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ImmunityBio signs $30M promissory note with Nant Capital (SOFR+8%, due Dec 31, 2023)","bullets":["Three $10M advances available; interest at Term SOFR + 8% per annum payable quarterly.","Net proceeds ~$29.85M after $150k origination fee (0.5%) paid to lender.","Proceeds to fund pre-commercialization, clinical development, R&D, capex, and general corporate purposes.","Lender Nant Capital is affiliate of Executive Chairman Dr. Patrick Soon-Shiong (related-party transaction).","Annual meeting results: all nine director nominees re-elected; Ernst & Young ratified as auditor."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-23-000076","json":"https://secwatch.observer/filing/0001326110-23-000076.json","markdown":"https://secwatch.observer/filing/0001326110-23-000076.md","text":"https://secwatch.observer/filing/0001326110-23-000076.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000076/0001326110-23-000076-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000076/ibrx-20230613.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T01:01:36.862269+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d532bdb2025e665fced508a55ad9253fc9324562","claim":"ImmunityBio, Inc. incurred loan of $30.0 million with Nant Capital, LLC at Term SOFR plus 8.0% per annum maturing December 31, 2023.","evidence_excerpt":"on June 13, 2023, the Company executed a $30.0 million promissory note with Nant Capital, LLC","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000076/0001326110-23-000076-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$30.0 million"},{"label":"Counterparty","value":"Nant Capital, LLC"},{"label":"Rate","value":"Term SOFR plus 8.0% per annum"},{"label":"Maturity","value":"December 31, 2023"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"2fc5737cfe46dbde985d60b725aa1a9826081d80","claim":"ImmunityBio, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-06-13 meeting.","evidence_excerpt":"Votes “For” Votes “Against” Abstentions “Broker Non-Votes” 374,132,354 270,094 278,602 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000076/0001326110-23-000076-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"},{"claim_id":"57d59d6c80e89a7f9b6ab63ea394e4d2130925ca","claim":"ImmunityBio, Inc. shareholders approved Election of Nine Directors at the 2023-06-13 meeting.","evidence_excerpt":"Nominee Votes “For” Votes “Withheld” “Broker Non-Votes” Patrick Soon-Shiong, M.D. 334,538,179 6,075,920 34,066,951 Cheryl L. Cohen 339,932,285 681,814 34,066,951 Richard Adcock 339,531,860 1,082,239 34,066,951 Michael D. Blaszyk 339,884,168 729,931 34,066,951 John Owen Brennan 337,964,499 2,649,600 34,066,951 Wesley Clark 338,703,037 1,911,062 34,066,951 Linda Maxwell, M.D. 340,016,716 597,383 34,066,951 Christobel Selecky 339,831,897 782,202 34,066,951 Barry J. Simon, M.D. 337,635,450 2,978,649 34,066,951","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326110/000132611023000076/0001326110-23-000076-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-13"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}